Drug Data Deals a Blow to Catabasis Pharmaceuticals Inc (CATB)

Catabasis Pharmaceuticals Inc (CATB) short sellers are celebrating the stock's 26% plunge

Jun 8, 2016 at 2:07 PM
facebook twitter linkedin


Biotech Catabasis Pharmaceuticals Inc (NASDAQ:CATB) is getting crushed this afternoon, after the drugmaker's cholesterol drug failed in a mid-stage trial. At last check, the stock was down roughly 26% at $5.08, and earlier fell as far south as $4.78, putting CATB on track for its worst daily performance ever. This is business as usual for the shares, which have surrendered 36% of their value year-to-date.

CATB short sellers must be loving life right now. During the past two reporting periods, short interest on the stock spiked close to 15%. Now, 7.8% of CATB's float is sold short, which would take approximately four weeks to buy back, at the stock's typical trading levels. Of course, the shares are short-sale restricted today amid their steep sell-off.

On the other hand, it seems as though the brokerage crowd is beginning to sing a different tune. Heading into today, all three analysts tracking CATB had doled out "strong buy" recommendations. Plus, the stock's consensus 12-month price target stood at $21.50 -- record-high territory, and quadruple the shares' current perch.

Since the drug data was released, signs of pessimism have begun cropping up. Specifically, Catabasis Pharmaceuticals Inc (NASDAQ:CATB) has seen its price target cut at Wedbush (to $17), Citigroup (to $8), and Oppenheimer (to $23).

Sign up now for Schaeffer's Market Recap to get all the day's big stock movers, must-know technical levels, and top economic stories straight to your inbox.

 

 

 

These investors are using the market's volatility to their advantage and scoring triple-digit gains on many of their trades.

Even in today's sideways bear market, this trading strategy has continued to provide consistency and profitability to a small group of investors. By using this approach, these traders are removing directional risk and still hitting triple-digit returns. If you want access to this strategy, and lower risk with higher returns sounds good to you, then don't wait another minute.

Join us now to receive our next trades the moment they come out!

 

Common mistakes options traders make
 


 


 
Special Offers from Schaeffer's Trading Partners